Vogenx, Inc. (VOGX)
NASDAQ: VOGX · Real-Time Price · USD
14.09
+1.09 (8.38%)
At close: Aug 13, 2026, 4:00 PM EDT
15.54
+1.45 (10.29%)
After-hours: Aug 13, 2026, 4:48 PM EDT
Company Description
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D).
It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Vogenx, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Aug 12, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | James Green |
Contact Details
Address: 3901 Barrett Drive, Suite 300 Raleigh, North Carolina 27609 United States | |
| Phone | 919 659 5677 |
| Website | vogenx.com |
Stock Details
| Ticker Symbol | VOGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 1903784 |
| CUSIP Number | 92859A106 |
| ISIN Number | US92859A1060 |
| Employer ID | 86-3697324 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James Green | President, Chief Executive Officer and Director |
| William Wilkison, Ph.D. | Chief Scientific Officer and Director |
| Steven Delmar | Chief Financial Officer, Corporate Secretary and Director |
| Timothy Boris | Director |
| Richard Gorman | Director |
| Peter Pieraccini | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2026 | 8-K | Current Report |
| Aug 13, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 12, 2026 | 424B4 | Prospectus |
| Aug 11, 2026 | EFFECT | Notice of Effectiveness |
| Aug 11, 2026 | CERT | Certification by an exchange approving securities for listing |
| Aug 10, 2026 | 8-A12B | Registration of securities |
| Aug 10, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 29, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 15, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 30, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |